All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK. We asked, Measurable residual disease (MRD)- AML, is a reduced intensity conditioning regimen enough?
MRD-AML, is RIC enough?
Craddock begins by highlighting why allogeneic hematopoietic stem cell transplantation now plays a role in high risk adult AML. He goes on to outline what we know about the impact of pre-transplant MRD on transplant outcome. Finally, he discusses a lack of randomized data and highlights that myeloablative regimes are safe for fit patients under 50, so there is no reason not to utilize a reduced intensity regimen.
Charles Craddock | EBMT 2019 | Optimization of the graft-versus-leukemia effect
At the 45th Annual Meeting of the EBMT, Charles Craddock talks about optimizing the graft-versus-leukemia effect
The passing of Professor Francesco Lo Coco: the great pioneer of targeted therapy leaves the leukemia community
Professor Francesco Lo Coco passed away on March 3, 2019.
Subscribe to get the best content related to AML delivered to your inbox